James Dunn, MD
Ophthalmology · Plymouth Meeting, PANPI 1932140209
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,320 of the $7,255 with a category attached, or 87.1%. Regeneron accounts for 64.8% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $4,767 and has fallen 83.5% since, to $786 in 2025.
Across 9 payments — averaging $806.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$5K
- Eyepoint US, Inc.$2K
- Abbott$786
- Boston Scientific$121
- AbbVie$29
Across 18 payments — averaging $6003.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$82K
- Gilead$26K
What the payments were for
- Consulting fees$6,32087%
- Travel & lodging$78611%
- Food & beverage$1502%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 2 | $4,700 |
| Eyepoint US, Inc. | 1 | $1,620 |
| Abbott | 3 | $786 |
| Boston Scientific | 2 | $121 |
| AbbVie | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,255 in reported general payments places this provider in the 85th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 49 | $336,824 |
| Prednisolone Acetate | 533 | $26,461 |
| Mycophenolate Mofetil | 85 | $22,317 |
| Difluprednate | 98 | $14,538 |
| CombiganBrimonidine Tartrate/Timolol | 41 | $11,659 |
| ProlensaBromfenac Sodium | 14 | $5,506 |
| MethotrexateMethotrexate Sodium | 147 | $4,543 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $4,506 |
| Ketorolac Tromethamine | 164 | $4,010 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 24 | $3,752 |
| Cyclosporine | 11 | $3,446 |
| Brimonidine Tartrate | 106 | $3,175 |
| ValacyclovirValacyclovir Hcl | 76 | $3,046 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 158 | $2,865 |
| Timolol Maleate | 178 | $1,608 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan | $29 | $11,65941 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Plymouth Meeting
- Carl RegilloPlymouth Meeting$721K
- Michael KlufasPlymouth Meeting$393K
- Ajay KuriyanPlymouth Meeting$226K
- Allen HoPlymouth Meeting$225K
- Sunir GargPlymouth Meeting$216K
- Yoshihiro YonekawaPlymouth Meeting$95K
- Omesh GuptaPlymouth Meeting$85K
- Sonia MehtaPlymouth Meeting$49K
- Julia HallerPhiladelphia$1.5M
- Francis MahPittsburgh$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.